Regeneron Pharmaceuticals, Inc.
LSE: 0R2M.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Leonard S. Schleifer
- Employees
- 15,158
- Headquarters
- Tarrytown, United States
- IPO year
- 2014
- Market cap
- $77.2B
- Website
- https://www.regeneron.com
Loading 0R2M…
Loading profile data…Frequently asked questions about 0R2M
What does Regeneron Pharmaceuticals, Inc. (0R2M.L) do?
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
Where does 0R2M.L trade?
Regeneron Pharmaceuticals, Inc. (0R2M.L) trades on the London Stock Exchange.
What sector is 0R2M.L in?
Regeneron Pharmaceuticals, Inc. (0R2M.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Regeneron Pharmaceuticals, Inc.?
Leonard S. Schleifer is the chief executive officer of Regeneron Pharmaceuticals, Inc. (0R2M.L).
Where is Regeneron Pharmaceuticals, Inc. headquartered?
Regeneron Pharmaceuticals, Inc. is headquartered in United States.
Does 0R2M.L pay a dividend?
Yes — Regeneron Pharmaceuticals, Inc. (0R2M.L) paid a trailing twelve-month dividend of USD 3.58 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 0R2M.L go public?
Regeneron Pharmaceuticals, Inc. (0R2M.L) completed its initial public offering in 2014.